Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > NR Liminal BioSciences to Present At H.C. Wainwright & Co. 3

<< Previous

Bullboard Posts

Next >>

Comment by GunnerGon Oct 21, 2019 11:49am

41 Views

Post# 30251329

RE:RE:RE:RE:NR Liminal BioSciences to Present At H.C. Wainwright & Co. 3

You do realize PBI 4547 has been talked about for years.

Also, a long long way to go before anything is brought to market.

realstocky wrote:
well the new owners are bringing it to market...presentation today!

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Oct. 18, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (TSX: LMNL) (OTCQX: PFSCF) ("Liminal BioSciences" or the "Company"), a clinical-stage small molecules company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today, that members of the management team will provide a presentation on PBI-4547 as a potential treatment for NASH at the H.C. Wainwright & Co. 3^rd Annual NASH Investor Conference at 16:20 ET on Monday, October 21, 2019 in New York, USA.